Provided by Tiger Trade Technology Pte. Ltd.

Oculis

13.18
+0.09500.73%
Post-market: 13.250.0700+0.53%19:30 EDT
Volume:150.39K
Turnover:1.97M
Market Cap:813.63M
PE:-7.68
High:13.25
Open:13.10
Low:12.87
Close:13.09
52wk High:34.48
52wk Low:10.52
Shares:61.73M
Float Shares:53.44M
Volume Ratio:0.86
T/O Rate:0.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7151
EPS(LYR):-2.3888
ROE:-43.70%
ROA:-24.95%
PB:2.98
PE(LYR):-5.52

Loading ...

Company Profile

Company Name:
Oculis
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
60
Office Location:
Bahnhofstrasse 20,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Directors

Name
Position
Anthony Rosenberg
Chairman of the Board
Riad Sherif
Chief Executive Officer and Director
Arshad M. Khanani
Director
Christina Ackermann
Director
Geraldine O'Keeffe
Director
Lionel Carnot
Director
Martijn Kleijwegt
Director
Robert K. Warner
Director

Shareholders

Name
Position
Riad Sherif
Chief Executive Officer and Director
Sylvia Cheung
Chief Financial Officer
Pall Ragnar Johannesson
Chief Business Officer